Dactolisib (BEZ235)

Name: Dactolisib (BEZ235)
Brand: Selleck Chemicals
SKU: S1009
Rating: 5 (335 reviews)

For research use only.

Catalog No.S1009 Synonyms: NVP-BEZ235

335 publications

CAS No. 915019-65-7

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

Selleck's Dactolisib (BEZ235) has been cited by 335 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Nat Microbiol, 2020, 10.1038/s41564-020-0782-1

PubMed: 32895527 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )
Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

Cancer Med, 2020, 10.1002/cam4.3432

PubMed: 32976685 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )

Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1900-1918

PubMed: 32642299 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29926

PubMed: 32654229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):524

PubMed: 32963283 ( click the link to review the publication )

Biochem Genet, 2020, 10.1007/s10528-020-09982-x

PubMed: 32671511 ( click the link to review the publication )

Elife, 2020, 9:e53367

PubMed: 32513387 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-4245

PubMed: 32605911 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 43(2):223-235

PubMed: 31776938 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11487

PubMed: 32661241 ( click the link to review the publication )

Cell Rep, 2020, 32(3):107933

PubMed: 32697996 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )
Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )

J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )
Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

PLoS One, 2019, 14(5):e0216603

PubMed: 31100067 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

ACS Pharmacol Transl Sci, 2019,

PubMed: 32259061 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2018,

PubMed: 30224486 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )
Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )
Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(2):e0191890

PubMed: 29389967 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )
Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

J Med Chem, 2017,

PubMed: 28471660 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

Mol Oncol, 2017, 11(9):1130-1142

PubMed: 28544747 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10612

PubMed: 28878291 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )
Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7265-7275

PubMed: 27980219 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016,

PubMed: 27849011 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )
Biol Chem, 2016, 397(7):671-8

PubMed: 26910743 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0162634

PubMed: 27611696 ( click the link to review the publication )

Thorac Cancer, 2016, 7(3):279-87

PubMed: 27148412 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(15):19214-27

PubMed: 27036037 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )
Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

Cancer Sci, 2015,

PubMed: 25483727 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

BMC Cancer, 2015,

PubMed: 26205886 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 26270481 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )
Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

Am J Cancer Res, 2014,

PubMed: 25520871 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )
Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

Oncotarget, 2014, 5(18):8737-49

PubMed: 25228590 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12862-76

PubMed: 25404640 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )
Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012,

PubMed: 22989520 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Targets

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	View More
4 nM	5 nM	6 nM	7 nM	21 nM	View More

In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. ^[1] BEZ235 is an mTORC1/2 catalytic inhibitor. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MXXBcpRqdWmlcn;ibYFtKEG\|c3H5		NVjHOpR2OThiaB?=	MkPGSG1UVw>?	MWTBcpRqfHK7cHHuc5NwdWGuIHHjeIl3cXS7IIfpeIghTUN3MDDv[kAxNjByMkWg{txO	NFj4THAzPDhyNUm0Oi=>
MCF7	M3XrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlToNE4xOS1zMECg{txO	NXvlZlA4PDhiaB?=	MlPkSG1UVw>?	MmXXTWM2OD1yLkezJO69VQ>?	MnK0NlM5PzF7MES=
HCT116	NYKxVHE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUWwMlAyNTFyMDFOwG0>	NIjISXY1QCCq	NGPaTplFVVOR	M3\XVmlEPTB;MT6xOkDPxE1?	M3X6XFI{QDdzOUC0
U87MG	M320e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVeyd3VYOC5yMT2xNFAh\|ryP	MV20PEBp	MmDjSG1UVw>?	MWTJR\|UxRTFwM{Kg{txO	NVHP[40{OjN6N{G5NFQ>
HBC4	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrWV49GOC5yMT2xNFAh\|ryP	NYW5RYxwPDhiaB?=		NITWZZZNd2diR1m1NF0uQC54MTDN	NXf0coxQOjJ\|M{[yOFY>
BSY1	M{mzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPSTGxSOC5yMT2xNFAh\|ryP	MlzkOFghcA>?		MnLUUI9oKEeLNUC9MVgvPDhiTR?=	NEjCeIszOjN\|NkK0Oi=>
HBC5	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfDNE4xOS1zMECg{txO	Mn;uOFghcA>?		MYrMc4chT0l3ME2tO{45PyCP	MmfiNlI{OzZ{NE[=
MCF7	NVy4SVRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3qdYoxNjBzLUGwNEDPxE1?	NXfXbJRMPDhiaB?=		Ml\KUI9oKEeLNUC9MVgvOTZiTR?=	MX6yNlM{PjJ2Nh?=
MDA-MB-231	NFvZWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTKNm5rOC5yMT2xNFAh\|ryP	NES1Umo1QCCq		MUTMc4chT0l3ME2tPE4xQSCP	MX6yNlM{PjJ2Nh?=
U251	NEnqbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXVNE4xOS1zMECg{txO	NVT2UGZYPDhiaB?=		MWLMc4chT0l3ME2tO{43PiCP	NFjPUpgzOjN\|NkK0Oi=>
SF268	M1vuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnSNE4xOS1zMECg{txO	NU\3WJZ[PDhiaB?=		NIfWc\|RNd2diR1m1NF0uPy57MjDN	NWD6cotkOjJ\|M{[yOFY>
SF295	M1zGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml60NE4xOS1zMECg{txO	MXi0PEBp		NHHTTI5Nd2diR1m1NF0uQC5\|MTDN	MX[yNlM{PjJ2Nh?=
SF539	M2jyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWSwMlAyNTFyMDFOwG0>	Mn7BOFghcA>?		NGXzWmNNd2diR1m1NF0uQC53OTDN	NGrzRoIzOjN\|NkK0Oi=>
SNB75	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWwMlAyNTFyMDFOwG0>	NUDPbWVEPDhiaB?=		NWPjS3ZZVG:pIFfJOVA:NThwNUigUS=>	MnKwNlI{OzZ{NE[=
SNB78	NXnuSo86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnCOYl1OC5yMT2xNFAh\|ryP	MVe0PEBp		MU\Mc4chT0l3ME2tPE43PSCP	NVfhZ3lHOjJ\|M{[yOFY>
HCC2998	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHXUGJ1OC5yMT2xNFAh\|ryP	M17jW\|Q5KGh?		NELhenRNd2diR1m1NF0uQC5yNTDN	M4\2T\|IzOzN4MkS2
KM12	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3KNE4xOS1zMECg{txO	MYi0PEBp		MkLMUI9oKEeLNUC9MVcvPTRiTR?=	NHzPU5QzOjN\|NkK0Oi=>
HT-29	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{S3e\|AvODFvMUCwJO69VQ>?	NX3iV\|k4PDhiaB?=		M4fPbmxw\yCJSUWwQU04Njd3IF2=	M1PmO\|IzOzN4MkS2
HCT15	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkH5NE4xOS1zMECg{txO	M1j3fFQ5KGh?		M{nYb2xw\yCJSUWwQU05NjB\|IF2=	MXSyNlM{PjJ2Nh?=
HCT116	NW\V[mlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTFSIIyOC5yMT2xNFAh\|ryP	M3nScFQ5KGh?		MlywUI9oKEeLNUC9MVcvPjFiTR?=	MojvNlI{OzZ{NE[=
NCI-H23	Ml7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmCyNE4xOS1zMECg{txO	NGG3VWY1QCCq		MmDDUI9oKEeLNUC9MVcvPjRiTR?=	MnnmNlI{OzZ{NE[=
NCI-H226	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmH4NE4xOS1zMECg{txO	NHqzWJM1QCCq		NGi0VJVNd2diR1m1NF0uQC52NDDN	MoXsNlI{OzZ{NE[=
NCI-H522	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\Y[5ExNjBzLUGwNEDPxE1?	M2XXNVQ5KGh?		M1rRfGxw\yCJSUWwQU05NjR3IF2=	MkTRNlI{OzZ{NE[=
NCI-H438	NXzJPJZzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPDe3AxNjBzLUGwNEDPxE1?	Mn\1OFghcA>?		MmXKUI9oKEeLNUC9MVgvOTFiTR?=	M2ruUVIzOzN4MkS2
A549	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHWVXIxNjBzLUGwNEDPxE1?	MlnQOFghcA>?		M1\sZmxw\yCJSUWwQU05NjB5IF2=	NEPhXmUzOjN\|NkK0Oi=>
DMS273	M2i3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[1e\|AvODFvMUCwJO69VQ>?	NULBW4N3PDhiaB?=		NEnGbW5Nd2diR1m1NF0uPy56MDDN	MnXWNlI{OzZ{NE[=
DMS114	NX3teWZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnGUZp2OC5yMT2xNFAh\|ryP	NILaTms1QCCq		MnPPUI9oKEeLNUC9MVgvOzliTR?=	M3qyeFIzOzN4MkS2
LOXIMVI	NVn5epZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;ENE4xOS1zMECg{txO	NHnYcYY1QCCq		MnfrUI9oKEeLNUC9MVgvPjZiTR?=	MY[yNlM{PjJ2Nh?=
OVCAR3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWCwMlAyNTFyMDFOwG0>	NXTWeJR7PDhiaB?=		NFzhOVNNd2diR1m1NF0uQC5zNzDN	NVTTN\|I3OjJ\|M{[yOFY>
OVCAR4	M1vHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2O4XlAvODFvMUCwJO69VQ>?	NWrRTmc4PDhiaB?=		Mn75UI9oKEeLNUC9MVgvPThiTR?=	NYLsOllpOjJ\|M{[yOFY>
OVCAR5	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLlNE4xOS1zMECg{txO	NVLNRoh{PDhiaB?=		MYLMc4chT0l3ME2tO{42PyCP	NIq3ZZozOjN\|NkK0Oi=>
OVCAR8	NIXFO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvTc5M1OC5yMT2xNFAh\|ryP	MVO0PEBp		NIHSfVNNd2diR1m1NF0uPy56NDDN	NXW0cHZ{OjJ\|M{[yOFY>
SKOV3	NYn4cmMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkC2NE4xOS1zMECg{txO	NU\pPZVqPDhiaB?=		MWHMc4chT0l3ME2tPE41OSCP	NVPnc\|NiOjJ\|M{[yOFY>
RXF631L	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHIUXUxNjBzLUGwNEDPxE1?	M{exW\|Q5KGh?		NIHpTVFNd2diR1m1NF0uQC5{MTDN	NU\6R4t3OjJ\|M{[yOFY>
ACHN	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPYNE4xOS1zMECg{txO	M3TuSFQ5KGh?		MUnMc4chT0l3ME2tO{46PSCP	NFTYNmczOjN\|NkK0Oi=>
St-4	Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rDelAvODFvMUCwJO69VQ>?	MnHzOFghcA>?		MVfMc4chT0l3ME2tO{41PyCP	NV7wTGlMOjJ\|M{[yOFY>
MKN1	NEH3TnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO3fYlvOC5yMT2xNFAh\|ryP	NYjKO3ZRPDhiaB?=		MV3Mc4chT0l3ME2tPE41OSCP	NWLqe\|ZoOjJ\|M{[yOFY>
MKN7	M1TxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLWNE4xOS1zMECg{txO	MmfsOFghcA>?		MVXMc4chT0l3ME2tO{43QCCP	NXLtU4J5OjJ\|M{[yOFY>
MKN28	NGfVT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorMNE4xOS1zMECg{txO	MXq0PEBp		NIn1VVZNd2diR1m1NF0uPy5yNzDN	MoXvNlI{OzZ{NE[=
MKN45	MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV[wMlAyNTFyMDFOwG0>	NULP[2s3PDhiaB?=		NIfTe3JNd2diR1m1NF0uQC5\|NDDN	MmDWNlI{OzZ{NE[=
MKN74	NYizS4VxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\1doIxNjBzLUGwNEDPxE1?	NIPlNWk1QCCq		NHvQTpJNd2diR1m1NF0uPy52MjDN	NVXpNGxoOjJ\|M{[yOFY>
DU145	M3K5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnSNE4xOS1zMECg{txO	MlnVOFghcA>?		M3:1fWxw\yCJSUWwQU05NjF4IF2=	MlLINlI{OzZ{NE[=
PC3	M1i4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFW0c2gxNjBzLUGwNEDPxE1?	NI\NZVk1QCCq		MYfMc4chT0l3ME2tPE43PiCP	NH;BNmQzOjN\|NkK0Oi=>
Trypanosoma brucei brucei	M1f4RmZ2dmO2aX;uJGF{e2G7	MkiyNlAxKG6P	NYf5fYw{OTJiaB?=	MUnEUXNQ	NYD0dYZoTGWlcnXhd4UhcW5icHjvd5Bpd3SrZInsJIlvd3OrdH;sJJBpd3OyaHH0[UBt\X[nbB?=	NIrXdHozPDhyNUm0Oi=>
Trypanosoma brucei brucei	NXjVe3JMTnWwY4Tpc44hSXO\|YYm=		M1jjdVE5KGh?	NF22bFdFVVOR	NFL0THBKdmirYnn0bY9vKG:oIILlZ4VxfG:{LX3l[IlifGWmIHXu[I9kgXSxc3nzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIITyZY5{\mW{cnnuJJVxfGGtZR?=	MkTNNlQ5ODV7NE[=
Trypanosoma brucei brucei	MXvGeY5kfGmxbjDBd5NigQ>?	MUKyNFAhdk1?	MUexNkBp	NVfxNWNjTE2VTx?=	Mme2SYZn\WO2IH;uJJNxcGmwZ3;tfYxmcW5ibHX2[Yw>	M2XUUlI1QDB3OUS2
Trypanosoma brucei brucei	M1fwOWZ2dmO2aX;uJGF{e2G7	NXHBTIxwOjByIH7N	MVixNkBp	M3fme2ROW09?	MmKySYZn\WO2IH;uJJBpd3OyaHH0bYR6dGOqb3zpcoUhdGW4ZXy=	NUjEW4l2OjR6MEW5OFY>
UM-UC-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XFfGlEPTB;M{G1JJBO	NGnme4xUSU6JRWK=
SBC-1	NFH3VVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3n0NmlEPTB;N{SyJJBO	NYLYdoRZW0GQR1XS
MKN1	M3fyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlGyTWM2OD1{Lkigcm0>	NHfBeGhUSU6JRWK=
NCI-H720	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHJVGg2UUN3ME2zMlU4KG6P	M{jSNXNCVkeHUh?=
BFTC-909	NHKxRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rmNmlEPTB;Mz63NUBvVQ>?	M4f3OnNCVkeHUh?=
BPH-1	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1y2VGlEPTB;ND63OkBvVQ>?	NV\ZW5ZvW0GQR1XS
PC-3	NIO3cmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmi0TWM2OD13LkC5JI5O	Ml3sV2FPT0WU
AN3-CA	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoKzTWM2OD13LkW2JI5O	MVjTRW5ITVJ?
HN	NGDJWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTsUG9XUUN3ME21Mlk3KG6P	NUmw[XFlW0GQR1XS
HCC2218	NWjsfGdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7EZ5NrUUN3ME22MlYyKG6P	MkLPV2FPT0WU
KP-4	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPnTWM2OD15IH7N	NFjXO\|RUSU6JRWK=
LU-139	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInLe29KSzVyPUeuO\|chdk1?	MonYV2FPT0WU
ETK-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXi2SIVKUUN3ME23Mlg5KG6P	NHTEUpBUSU6JRWK=
Ramos-2G6-4C10	NGf1bXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRThwNEmgcm0>	MmHpV2FPT0WU
MHH-PREB-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTlwMUKgcm0>	NYS1d\|l6W0GQR1XS
DU-4475	NEnGRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTlwNESgcm0>	MXzTRW5ITVJ?
NCI-H1666	NFHteZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXG3ZZh5UUN3ME25MlcyKG6P	NIXyVW9USU6JRWK=
CAMA-1	NXqzfJB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDX[Y1KSzVyPUmuPEBvVQ>?	NEXWdJpUSU6JRWK=
TYK-nu	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LKfWlEPTB;OT65OEBvVQ>?	MWfTRW5ITVJ?
MFE-280	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYS1cY5wUUN3ME25Mlk6KG6P	MWXTRW5ITVJ?
A549	NXi1e2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXjWnFKSzVyPUGwMlE1KG6P	NXnWd2FpW0GQR1XS
769-P	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXmcnZKSzVyPUGwMlQ1KG6P	M{TXW3NCVkeHUh?=
L-363	NH7OS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnXR2JKSzVyPUGwMlY6KG6P	MoD6V2FPT0WU
ES8	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;ZT2lKSzVyPUGwMlkhdk1?	MmG3V2FPT0WU
PA-1	NIH1[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoD6TWM2OD1zMT64NkBvVQ>?	M2TKfXNCVkeHUh?=
Mewo	NUDaeod3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkmzTWM2OD1zMT65PUBvVQ>?	NXrNVXJxW0GQR1XS
HSC-3	M3LOd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorWTWM2OD1zMj6yNUBvVQ>?	NWTwZYhoW0GQR1XS
H4	NUjQSHd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTF{Lk[3JI5O	NULBR2tzW0GQR1XS
BB65-RCC	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;rb4RKSzVyPUGyMlczKG6P	MVjTRW5ITVJ?
NCI-H1793	NETrb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLDNnFbUUN3ME2xNk45OiCwTR?=	MV7TRW5ITVJ?
KARPAS-45	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUP0do5OUUN3ME2xN{42OSCwTR?=	NHjTPI9USU6JRWK=
GCT	NG[2T\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVXJR\|UxRTF\|Lk[4JI5O	MkfSV2FPT0WU
EoL-1	M3O0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF\|LkmzJI5O	MXnTRW5ITVJ?
LB2241-RCC	M3TmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLG[5BKSzVyPUG0MlAyKG6P	NGDXVmRUSU6JRWK=
ES5	MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\xTWM2OD1zND63OEBvVQ>?	MXTTRW5ITVJ?
LOXIMVI	M4PCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTF2Lkm5JI5O	MVPTRW5ITVJ?
COR-L105	NGLKZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXofZVkUUN3ME2xOU4xPCCwTR?=	MoDGV2FPT0WU
P12-ICHIKAWA	M3L0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTF3LkGgcm0>	M1fnZ3NCVkeHUh?=
CHL-1	M3mzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jlT2lEPTB;MUWuOFUhdk1?	NXWyPZR4W0GQR1XS
VMRC-RCZ	M13ZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTF3Lk[zJI5O	Mm\kV2FPT0WU
HH	NXnNVot7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3ewemlEPTB;MUWuO{BvVQ>?	MUjTRW5ITVJ?
NUGC-3	NWfDWo1ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFGybnZKSzVyPUG2MlM1KG6P	MmXIV2FPT0WU
EGI-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTF4LkSzJI5O	M3TKW3NCVkeHUh?=
OS-RC-2	NH70fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTF4LkS3JI5O	MnnPV2FPT0WU
MOLT-16	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnT1TWM2OD1zNz6xOUBvVQ>?	M{PpO3NCVkeHUh?=
NCI-H209	NVjlXZNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XBZmlEPTB;MUeuNlkhdk1?	NX3LRYdEW0GQR1XS
697	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFm1W3RKSzVyPUG3MlQ{KG6P	NVLSW5VLW0GQR1XS
D-56MG	M4X2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTF5Lk[5JI5O	NYnMTY95W0GQR1XS
VA-ES-BJ	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTF5LkizJI5O	MXPTRW5ITVJ?
EW-16	M{jUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTF6LkC0JI5O	NF7D[ZlUSU6JRWK=
HGC-27	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrvTWM2OD1zOD6wOkBvVQ>?	MX7TRW5ITVJ?
ES7	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzZTWM2OD1zOD6wPUBvVQ>?	M2PW[HNCVkeHUh?=
HuH-7	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfMXYpNUUN3ME2xPE41KG6P	NFvmbVZUSU6JRWK=
BCPAP	NGTGOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\6[YpKSzVyPUG4MlY2KG6P	MUjTRW5ITVJ?
SW1710	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvsTWM2OD1zOD63NkBvVQ>?	NYe5emlMW0GQR1XS
IST-MEL1	NYDMdm5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYD1[mNyUUN3ME2xPE44PyCwTR?=	NWnYSpBYW0GQR1XS
SF295	NIrhe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkX6TWM2OD1zOD65N{BvVQ>?	MoXuV2FPT0WU
RPMI-7951	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGeyN25KSzVyPUG5MlI5KG6P	NV7ZOIliW0GQR1XS
SF126	NHfVPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF7LkSxJI5O	MWnTRW5ITVJ?
GAMG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTF7LkS4JI5O	MW\TRW5ITVJ?
KNS-81-FD	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTF7LkW0JI5O	MYHTRW5ITVJ?
RT-112	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTF7Lk[2JI5O	MXHTRW5ITVJ?
DEL	NYG3eVNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP4TWM2OD1{MD60PUBvVQ>?	M{TVVXNCVkeHUh?=
CGTH-W-1	Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPVdXRKSzVyPUKwMlY{KG6P	NV3jUm06W0GQR1XS
HOS	NEDLSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTJzLkC2JI5O	NV\YfmJqW0GQR1XS
ES4	NVK0W5AzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjuOI1QUUN3ME2yNU4xQCCwTR?=	MoH0V2FPT0WU
RXF393	NEjHbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTJzLkS1JI5O	NX\T[og4W0GQR1XS
NCI-H2030	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmj4TWM2OD1{MT61NkBvVQ>?	MkTUV2FPT0WU
YH-13	NGLOWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDtTWM2OD1{MT64PEBvVQ>?	MWLTRW5ITVJ?
HT-1080	M3z4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTJzLkmzJI5O	NWj5N4txW0GQR1XS
NCI-SNU-1	NGHL[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTJzLkm1JI5O	NVewNG1CW0GQR1XS
G-402	NF7KSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfBdYNrUUN3ME2yNk4yPiCwTR?=	M4HlZ3NCVkeHUh?=
786-0	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TzeGlEPTB;MkKuNlkhdk1?	MY\TRW5ITVJ?
ME-180	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzVTWM2OD1{Mj60N{BvVQ>?	NGDBTWRUSU6JRWK=
NB69	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJ{LkWzJI5O	MkXQV2FPT0WU
J-RT3-T3-5	NUOxdppFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3POd2lEPTB;MkKuPVYhdk1?	MYHTRW5ITVJ?
TGBC1TKB	NVvobldTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPhfVloUUN3ME2yN{4xPSCwTR?=	MW\TRW5ITVJ?
SW780	M3;XRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXi2TZVlUUN3ME2yN{4yOyCwTR?=	NVjMW4FZW0GQR1XS
MG-63	M{\TWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYD5fpdkUUN3ME2yN{41PSCwTR?=	NWnRNGFLW0GQR1XS
BV-173	NH\kSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHraclhKSzVyPUKzMlg4KG6P	MlXGV2FPT0WU
CAL-51	NUC4SlVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;sSYt1UUN3ME2yN{45QSCwTR?=	NIr0ZYZUSU6JRWK=
A375	M4rKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\ETWM2OD1{Mz65N{BvVQ>?	NFXnRXZUSU6JRWK=
MEL-HO	MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\yPVNnUUN3ME2yOE4xPCCwTR?=	MWDTRW5ITVJ?
EFO-27	NFvOV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7JWmc4UUN3ME2yOE4{OyCwTR?=	MmrsV2FPT0WU
Hs-578-T	NVzPW4tGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGWyNYdKSzVyPUK0MlU5KG6P	NEDmR\|hUSU6JRWK=
NBsusSR	NYS0PJc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTJ2Lk[gcm0>	MoK5V2FPT0WU
CTB-1	Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXSU4tKSzVyPUK0MlY4KG6P	Mo\mV2FPT0WU
FTC-133	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTJ3LkGgcm0>	MnPFV2FPT0WU
MOLT-4	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\we3NKSzVyPUK1MlEzKG6P	NETwSldUSU6JRWK=
HO-1-N-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TrT2lEPTB;MkWuNVUhdk1?	NUDYXJZFW0GQR1XS
ES3	NHfsVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVqyfWZKUUN3ME2yOU4zOiCwTR?=	NV3YZ2tyW0GQR1XS
TI-73	M4fvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLKPXRNUUN3ME2yOU4zQCCwTR?=	NIW0OY9USU6JRWK=
MPP-89	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLiO4xKSzVyPUK1MlMzKG6P	MXnTRW5ITVJ?
KYSE-150	M2HvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7HNYlKSzVyPUK1Mlg6KG6P	NXrQVWJSW0GQR1XS
LXF-289	NGX2VIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\URYpsUUN3ME2yOk4xPCCwTR?=	M3TJZ3NCVkeHUh?=
SK-LU-1	NGG4c2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfvW41KSzVyPUK2MlE4KG6P	NWjrdlZFW0GQR1XS
HOP-92	NWPuN\|NDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1i0OWlEPTB;Mk[uOFghdk1?	M3m4VHNCVkeHUh?=
HuO9	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTJ4Lke2JI5O	NXfYTnB6W0GQR1XS
SW962	MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTJ4Lke2JI5O	NVT1[od6W0GQR1XS
RS4-11	M16wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;scWlEPTB;Mk[uPVEhdk1?	MULTRW5ITVJ?
NCI-H292	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTJ5IH7N	MXjTRW5ITVJ?
DB	NFnSOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3yTWM2OD1{Nz6zOkBvVQ>?	M1yzRXNCVkeHUh?=
SW1088	NIDSWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37qUWlEPTB;MkiuNlkhdk1?	M1LvdXNCVkeHUh?=
A204	NVPGWWlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\6UVBKSzVyPUK4MlQ4KG6P	NF;1W2pUSU6JRWK=
A3-KAW	M2nyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFK1VG9KSzVyPUK4MlY1KG6P	NG[5b5FUSU6JRWK=
MV-4-11	NYPq[XM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvEVVdKSzVyPUK4Mlchdk1?	NYj0OJRRW0GQR1XS
ES1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LSdGlEPTB;MkiuPFQhdk1?	NIjTZ4NUSU6JRWK=
ONS-76	M{G2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTJ7LkC1JI5O	M4n1Z3NCVkeHUh?=
D-263MG	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWT1VXNnUUN3ME2yPU4{PSCwTR?=	NIjuc3NUSU6JRWK=
U-2-OS	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJ7LkWgcm0>	MYLTRW5ITVJ?
T98G	NUPhcWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETPVZFKSzVyPUK5Mlg5KG6P	NFTMZnJUSU6JRWK=
GI-ME-N	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HJRWlEPTB;MkmuPVEhdk1?	MkLJV2FPT0WU
BHT-101	M3;6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrRTWM2OD1\|MD6wOUBvVQ>?	MojUV2FPT0WU
NOS-1	NVLZTJdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTNyLkGyJI5O	NIrSc5RUSU6JRWK=
AsPC-1	M13EW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTNyLkKgcm0>	MorVV2FPT0WU
QIMR-WIL	NFrw[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnMPJBkUUN3ME2zNE43KG6P	MmqxV2FPT0WU
JVM-3	NEXheIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrFTWM2OD1\|MD64N{BvVQ>?	NGjxeI9USU6JRWK=
KU-19-19	M333V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPoTWM2OD1\|MT6xN{BvVQ>?	NX\IPFdpW0GQR1XS
OVCAR-8	NIDIVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGqwVZFKSzVyPUOxMlI3KG6P	Ml:5V2FPT0WU
BEN	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrkbohKSzVyPUOxMlY{KG6P	MnrQV2FPT0WU
BE-13	NGHxc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfnTWM2OD1\|MT64NkBvVQ>?	NFnneVdUSU6JRWK=
EW-18	NYqwdZFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH4TItIUUN3ME2zNU45PiCwTR?=	MWDTRW5ITVJ?
ECC10	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHW2fnJKSzVyPUOxMlk2KG6P	MofhV2FPT0WU
CTV-1	NVLncXhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnTT3NKSzVyPUOyMlgzKG6P	MXzTRW5ITVJ?
COLO-800	NILxWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlyyTWM2OD1\|Mj65NkBvVQ>?	NVj6bo9uW0GQR1XS
A2058	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTBTWM2OD1\|Mz6yOUBvVQ>?	NWjQW5Q5W0GQR1XS
VM-CUB-1	NInBW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzuTWM2OD1\|Mz60N{BvVQ>?	NXOxVFNlW0GQR1XS
Ca9-22	NGDQXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkH0TWM2OD1\|Mz61OUBvVQ>?	MYfTRW5ITVJ?
COLO-684	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfmVXJKSzVyPUOzMlU5KG6P	NV35e2F4W0GQR1XS
RPMI-8226	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDjUHFKSzVyPUOzMlgzKG6P	MYfTRW5ITVJ?
SK-NEP-1	NIHTV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HnU2lEPTB;M{SuNVUhdk1?	NYXOflhsW0GQR1XS
Becker	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTN2LkKxJI5O	NWPpWnBQW0GQR1XS
NCI-H28	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnUWWM{UUN3ME2zOE41PCCwTR?=	MoLGV2FPT0WU
CAL-120	NYDodWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUfJR\|UxRTN2LkeyJI5O	NX3EbpYxW0GQR1XS
MDA-MB-157	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTN3LkSxJI5O	MmLlV2FPT0WU
OVCAR-5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PKZ2lEPTB;M{WuOFchdk1?	NFrsUG5USU6JRWK=
LAMA-84	NFjhU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfKPZVKSzVyPUO1Mlg4KG6P	NXXqOWZQW0GQR1XS
CAKI-1	NWK0UnA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnUSpBKSzVyPUO2MlQ{KG6P	MUfTRW5ITVJ?
Daoy	M2nIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3UfmNKSzVyPUO2Mlchdk1?	M3jpT3NCVkeHUh?=
CAL-62	NWLFWWNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LFO2lEPTB;M{[uPFYhdk1?	MnHLV2FPT0WU
8-MG-BA	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr2SZVKSzVyPUO3MlI2KG6P	MmjzV2FPT0WU
8505C	NYXBW\|M{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;UdmJKSzVyPUO3MlUyKG6P	NXvnOG5oW0GQR1XS
LNCaP-Clone-FGC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInDUXRKSzVyPUO3MlU6KG6P	NF:2SI5USU6JRWK=
CAL-39	NFXWV\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFH1bJRKSzVyPUO3Mlkhdk1?	MXfTRW5ITVJ?
MN-60	Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkGxTWM2OD1\|Nz65OkBvVQ>?	NEDWbZFUSU6JRWK=
RKO	NXnETYpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\JV\|dVUUN3ME2zPE4{OyCwTR?=	NYTPUmduW0GQR1XS
U251	M3viemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXGemtZUUN3ME2zPE41OyCwTR?=	NE[4TmNUSU6JRWK=
SJSA-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUj1cWl4UUN3ME2zPE42PCCwTR?=	NHz2eGVUSU6JRWK=
CAL-12T	MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGn5PGhKSzVyPUO4MlYhdk1?	MVzTRW5ITVJ?
HCC1419	NVizcIlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTN6LkexJI5O	MUDTRW5ITVJ?
CO-314	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWTsVHRHUUN3ME2zPE44PCCwTR?=	MnjiV2FPT0WU
LB1047-RCC	NVLGUXU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2q4XGlEPTB;M{iuPFEhdk1?	NVTGcnI3W0GQR1XS
A101D	NFrZSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTN6Lkm3JI5O	NUPYNYVLW0GQR1XS
MDA-MB-175-VII	NXTENppUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWqw[XJUUUN3ME2zPU42OSCwTR?=	NFGwOIZUSU6JRWK=
MZ2-MEL	M{HsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlL4TWM2OD1\|OT62OkBvVQ>?	NF7yZm1USU6JRWK=
NB5	NXHxbGpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTGTWM2OD12MD62OEBvVQ>?	NIroeXNUSU6JRWK=
G-401	M37hd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTRyLkiyJI5O	Mnv5V2FPT0WU
HT	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPURZdKSzVyPUSxMlAzKG6P	NH7wO2xUSU6JRWK=
8305C	M2nSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1myT2lEPTB;NEGuPFchdk1?	MljpV2FPT0WU
BHY	M{fqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1G3UmlEPTB;NEKuO\|Ihdk1?	M2DvXnNCVkeHUh?=
NTERA-S-cl-D1	NXewfI1xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTR\|IH7N	MlTHV2FPT0WU
T-24	M3HlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvFPWQ2UUN3ME20N{45OyCwTR?=	MXfTRW5ITVJ?
EPLC-272H	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfyN2dKSzVyPUS0MlM6KG6P	M2rFVHNCVkeHUh?=
PSN1	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorMTWM2OD12ND60JI5O	NGDQR5dUSU6JRWK=
NCI-H2452	NIf6ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nPW2lEPTB;NESuOVghdk1?	MmfVV2FPT0WU
KS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\6c4VKSzVyPUS0MlY3KG6P	MYHTRW5ITVJ?
HD-MY-Z	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml36TWM2OD12ND65NkBvVQ>?	NFjDcmxUSU6JRWK=
KNS-62	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmqwTWM2OD12NT6zPEBvVQ>?	NHPqUZVUSU6JRWK=
NOMO-1	NHza[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlryTWM2OD12NT64O{BvVQ>?	NX[yVmlSW0GQR1XS
SK-HEP-1	NVzybopOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnwTWM2OD12Nj6wOEBvVQ>?	Mn7vV2FPT0WU
IGR-1	NIPXU\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1uwNWlEPTB;NE[uNVMhdk1?	M4rRRXNCVkeHUh?=
KYSE-180	MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPITWM2OD12Nj6xO{BvVQ>?	NF;PWohUSU6JRWK=
EW-22	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYG1W3BTUUN3ME20Ok4zKG6P	NGLxTVhUSU6JRWK=
NCI-H1355	M1i1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLQNIFKSzVyPUS2MlM1KG6P	M3rKcXNCVkeHUh?=
DOHH-2	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTGTWM2OD12Nj6zO{BvVQ>?	MoHIV2FPT0WU
A4-Fuk	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnCfoV7UUN3ME20Ok42OiCwTR?=	NInJ[2FUSU6JRWK=
PC-14	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPNTWM2OD12Nj61O{BvVQ>?	MWrTRW5ITVJ?
TE-5	NIO3cpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnGTWM2OD12Nj64OEBvVQ>?	MYnTRW5ITVJ?
LB996-RCC	NV\TOZdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PKO2lEPTB;NEeuNVkhdk1?	MmP2V2FPT0WU
NCI-H1623	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rBXGlEPTB;NEeuO\|Yhdk1?	NIT0UpZUSU6JRWK=
NCI-H1155	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTR6LkOyJI5O	Mn74V2FPT0WU
LoVo	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfsOHBKSzVyPUS4MlQhdk1?	NUPr[JY3W0GQR1XS
MCF7	Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLmTWM2OD12OD61PEBvVQ>?	NEmwWlNUSU6JRWK=
AGS	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XveGlEPTB;NEiuO\|chdk1?	M2DMUHNCVkeHUh?=
PFSK-1	M3n2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPmclBzUUN3ME20PU4xPiCwTR?=	NWfMN\|c{W0GQR1XS
22RV1	NH\NeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\jbHdtUUN3ME20PU4xQSCwTR?=	MYfTRW5ITVJ?
COR-L23	NFPxXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13nUmlEPTB;NEmuNVYhdk1?	MoHVV2FPT0WU
D-283MED	NGXFZ\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPSbHJKSzVyPUS5MlYyKG6P	MlnGV2FPT0WU
SW982	NXTsVHdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrqbHpKSzVyPUS5MlkyKG6P	NY\1V\|NqW0GQR1XS
SW620	NXnMVFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPWPVIzUUN3ME21NE4{PiCwTR?=	M2m0VXNCVkeHUh?=
KYSE-140	M4X4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPjR2RkUUN3ME21NE42PSCwTR?=	NUi1dmNJW0GQR1XS
GCIY	M2TtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrvTWM2OD13MD62O{BvVQ>?	NV3Y[nFYW0GQR1XS
MHH-ESS-1	MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnkTWM2OD13MT65OUBvVQ>?	NVXMc2NzW0GQR1XS
D-423MG	NH\CSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFnhT2ZKSzVyPUWyMlA5KG6P	NF7TcFhUSU6JRWK=
SF539	NUXNO214T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGOwcHdKSzVyPUWyMlM2KG6P	M3;MVnNCVkeHUh?=
RPMI-2650	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTV{Lk[5JI5O	NV7NbG5EW0GQR1XS
GR-ST	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUf2WY57UUN3ME21Nk45PyCwTR?=	MXjTRW5ITVJ?
YKG-1	NGLHO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjiTWM2OD13MzDuUS=>	NIXydWZUSU6JRWK=
SK-MES-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\CWWlEPTB;NUOuNlYhdk1?	NIT2PXFUSU6JRWK=
HLE	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrROnFKSzVyPUWzMlQ4KG6P	MVLTRW5ITVJ?
RVH-421	M{KwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUT2VlRuUUN3ME21N{43PyCwTR?=	NYfWR4M2W0GQR1XS
C32	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfFcpc5UUN3ME21N{45OyCwTR?=	NGrEdWtUSU6JRWK=
GB-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TiNmlEPTB;NUSuNkBvVQ>?	MkDPV2FPT0WU
SNB75	NUXLVWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXpRZFKSzVyPUW0MlI3KG6P	NWC5UYFGW0GQR1XS
EM-2	NXfRT49QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX61Z4p2UUN3ME21OE41KG6P	MWrTRW5ITVJ?
RH-1	NVX0dGVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEf2NIRKSzVyPUW0Mlchdk1?	Mn;PV2FPT0WU
NKM-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fBeGlEPTB;NUSuPFEhdk1?	M2OydHNCVkeHUh?=
NCI-H2405	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33kZ2lEPTB;NUSuPFghdk1?	NIKzN2lUSU6JRWK=
KYSE-450	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrWTWM2OD13NT6xOkBvVQ>?	NH;0O2lUSU6JRWK=
A704	M3jCd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTV3LkW5JI5O	MmTlV2FPT0WU
HAL-01	NV3zRWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofTTWM2OD13NT64N{BvVQ>?	MUfTRW5ITVJ?
TE-11	NFzIPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTV3Lkm5JI5O	NHzDXG1USU6JRWK=
DOK	NV7WU2xCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PFRWlEPTB;NU[uNFIhdk1?	M3WxfnNCVkeHUh?=
KY821	NXewTpNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzON4dCUUN3ME21Ok4zKG6P	M3\BVXNCVkeHUh?=
KGN	NFHMPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTV4LkOyJI5O	M3Gxc3NCVkeHUh?=
MC116	M1LaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXewS5FYUUN3ME21O{45KG6P	NGnQUZBUSU6JRWK=
PANC-08-13	NUXtSJY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTV6LkCxJI5O	MnzCV2FPT0WU
KE-37	NWH1[HVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTV6Lke3JI5O	NHTkTWZUSU6JRWK=
KYSE-410	NYm0NoxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTV7LkS3JI5O	MmfmV2FPT0WU
RO82-W-1	M4LReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTV7Lkmgcm0>	M1rUVXNCVkeHUh?=
M14	M3TQTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjtPFRWUUN3ME22NE4xPCCwTR?=	M1rGWHNCVkeHUh?=
GI-1	NF;DR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\2bmlEPTB;NkCuN{BvVQ>?	Mn\KV2FPT0WU
ML-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHUTWM2OD14MD62NkBvVQ>?	NWixU\|QzW0GQR1XS
BFTC-905	M3vwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LN[mlEPTB;NkCuOlUhdk1?	M3u1XHNCVkeHUh?=
DMS-273	MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTZyLki3JI5O	NV[0UmhlW0GQR1XS
MDA-MB-361	NGHmVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTZzIH7N	M3TCNHNCVkeHUh?=
MSTO-211H	MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\0SHFKUUN3ME22N{42OSCwTR?=	M4LHWHNCVkeHUh?=
MEG-01	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTZ\|LkWyJI5O	M4DGeHNCVkeHUh?=
M059J	MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2C4OWlEPTB;NkOuOVghdk1?	M4flNnNCVkeHUh?=
LN-405	NGO3cZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fC[2lEPTB;NkOuPFUhdk1?	M3j2TXNCVkeHUh?=
NCI-H1581	MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWL3R5RDUUN3ME22OE4xOyCwTR?=	NFmyd4xUSU6JRWK=
TCCSUP	NFz0eHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjVT5VDUUN3ME22OE42OyCwTR?=	MYXTRW5ITVJ?
SW872	NULufXRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nLNmlEPTB;NkSuOVchdk1?	NGHpOFJUSU6JRWK=
KYSE-510	M2n3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHjTWM2OD14NT63OUBvVQ>?	MlPOV2FPT0WU
NCI-H1792	NIrzWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DOfGlEPTB;Nk[uNVUhdk1?	NEDibm5USU6JRWK=
SW13	NF;yVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\SfmlEPTB;Nk[uOUBvVQ>?	MkGwV2FPT0WU
TE-8	NVLyT5NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1KzV2lEPTB;Nk[uOVIhdk1?	M1vpOXNCVkeHUh?=
SCH	NYLDNm1jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjXW4FKSzVyPU[3MlEhdk1?	Mnj2V2FPT0WU
NEC8	M2C1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnBU4dnUUN3ME22O{4zPCCwTR?=	NW[4dVlEW0GQR1XS
HuO-3N1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX25TGlzUUN3ME22O{4{OSCwTR?=	M1:4cXNCVkeHUh?=
EFM-19	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTZ5LkWgcm0>	Mo\5V2FPT0WU
HEC-1	NHPaXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTZ5LkWyJI5O	MX;TRW5ITVJ?
T47D	M{HEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjSXmtKSzVyPU[3Mlg4KG6P	MmHTV2FPT0WU
SNU-423	MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVy0e4FTUUN3ME22O{46QCCwTR?=	NYLXR5VoW0GQR1XS
WM-115	MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHQcYFKSzVyPU[4MlE1KG6P	NGLtUnNUSU6JRWK=
CaR-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTZ6LkK1JI5O	NU\HRlBSW0GQR1XS
KU812	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTWUXFlUUN3ME22PE43QSCwTR?=	MlLFV2FPT0WU
AM-38	NHXjTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTZ7LkOxJI5O	NUXVelF4W0GQR1XS
KOSC-2	NEfXTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGS0PHhKSzVyPU[5Mlk4KG6P	MVfTRW5ITVJ?
MC-IXC	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTdyLkC4JI5O	MmjDV2FPT0WU
SCC-4	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvQS5FKSzVyPUexMlM5KG6P	NVvMU21bW0GQR1XS
Calu-3	NXTFOXVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfkTWM2OD15MT65PEBvVQ>?	NVrwUJBQW0GQR1XS
RPMI-8866	NVHhOmNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkH0TWM2OD15Mj64NkBvVQ>?	MlXaV2FPT0WU
OVCAR-4	NYPoOZVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnTTWM2OD15Mz6zOkBvVQ>?	NIjH[pRUSU6JRWK=
OAW-42	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvEcnBKSzVyPUezMlM6KG6P	MVHTRW5ITVJ?
ATN-1	NIC3SHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvOXmRKSzVyPUezMlg4KG6P	NUXSPG5xW0GQR1XS
CHP-212	M3LMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nZd2lEPTB;N{SuPVUhdk1?	MV;TRW5ITVJ?
C2BBe1	NVjqUo9mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPIWIMyUUN3ME23OU4xOyCwTR?=	MV\TRW5ITVJ?
A498	NX\WfXJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEH0bWFKSzVyPUe1MlE2KG6P	NXvqSGl3W0GQR1XS
SH-4	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTd3LkKxJI5O	MlrTV2FPT0WU
SNU-449	MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUf5[IE{UUN3ME23OU44QSCwTR?=	NVHSN3FTW0GQR1XS
RD	NUDDcHgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHPTWM2OD15NT64OkBvVQ>?	MmLvV2FPT0WU
PANC-03-27	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTd4LkK1JI5O	M4jCUXNCVkeHUh?=
S-117	NIfMPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUSzfJloUUN3ME23Ok4zPyCwTR?=	NFvkSJBUSU6JRWK=
SK-MEL-2	NGDsVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnnWZlKSzVyPUe2Mlc2KG6P	NHTJTVBUSU6JRWK=
LK-2	M{TXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTd5LkC1JI5O	NV3MXIt2W0GQR1XS
CP50-MEL-B	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HkfWlEPTB;N{euOEBvVQ>?	NGfuTYtUSU6JRWK=
647-V	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjqTWM2OD15OD6wO{BvVQ>?	NYH6U4MyW0GQR1XS
LU-134-A	NVK1UYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\5VmlEPTB;N{muNFMhdk1?	MmrSV2FPT0WU
5637	M{f5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml7CTWM2OD15OT6yN{BvVQ>?	MmC0V2FPT0WU
NCI-H1437	M2XWUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrhbpZKSzVyPUiwMlUhdk1?	NGSwfG1USU6JRWK=
NCI-H460	NEnCdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1H0SGlEPTB;OEGuNlMhdk1?	NWHLWWhKW0GQR1XS
BxPC-3	NXTzdld7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHP0UWNKSzVyPUixMlQ3KG6P	NHzqN5pUSU6JRWK=
CAN	MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPFPI85UUN3ME24NU45PCCwTR?=	NWnrVYdtW0GQR1XS
KINGS-1	NUTnSJdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXS2bZJrUUN3ME24Nk4{OiCwTR?=	NHHFWlhUSU6JRWK=
OCUB-M	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfMRXNtUUN3ME24Nk41OSCwTR?=	NYX5SINiW0GQR1XS
KALS-1	NIXjSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDGZ4xiUUN3ME24Nk42PCCwTR?=	MkfsV2FPT0WU
OCI-AML2	M1fMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWKyOYt{UUN3ME24Nk43OSCwTR?=	NFL4ZXFUSU6JRWK=
A253	M3;GS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHj5d\|dKSzVyPUiyMlY2KG6P	Mn70V2FPT0WU
LCLC-97TM1	NXvobok1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvRTWM2OD16Mj64OkBvVQ>?	NYraSHVrW0GQR1XS
NCI-H520	M2jmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\3cIp2UUN3ME24N{4xPiCwTR?=	MV3TRW5ITVJ?
P30-OHK	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XDTGlEPTB;OEOuOUBvVQ>?	Ml\rV2FPT0WU
SBC-5	MmXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPzfmdKSzVyPUizMlUzKG6P	MV3TRW5ITVJ?
HCE-T	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TJZmlEPTB;OEOuO\|Qhdk1?	NVfWb5duW0GQR1XS
JEG-3	M4DEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLrXnYzUUN3ME24OE4yKG6P	Mk\YV2FPT0WU
KG-1	NV7WcZBOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;BTWM2OD16ND6yOEBvVQ>?	NUTMSFlMW0GQR1XS
MIA-PaCa-2	NGfydHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHzEOpFKSzVyPUi0MlU1KG6P	M2XmUnNCVkeHUh?=
CAL-33	M1HXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjOVmVKSzVyPUi1MlA5KG6P	NX\K[5dqW0GQR1XS
639-V	NFPnbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\sTWM2OD16NT60NkBvVQ>?	M3Xsd3NCVkeHUh?=
NCI-H1048	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTh4LkOxJI5O	MYPTRW5ITVJ?
NCI-H1573	M2Pmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnuzTWM2OD16Nz60PEBvVQ>?	NV7HZ5FFW0GQR1XS
NCI-H2228	NWTkdG5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTh6LkK2JI5O	M4ni[HNCVkeHUh?=
NB14	NG\XUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnqRpVtUUN3ME24PE4{KG6P	NXXIUZZtW0GQR1XS
SCC-25	M4XIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTWTWM2OD16OT64NkBvVQ>?	NH7KXGFUSU6JRWK=
A431	NWnveXg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PKSmlEPTB;OEmuPVchdk1?	NVSyUYIzW0GQR1XS
SN12C	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFT2boZKSzVyPUmwMlYzKG6P	NFnNToZUSU6JRWK=
HuCCT1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrYNZQ5UUN3ME25NE44PiCwTR?=	Mlm4V2FPT0WU
LS-123	M{i4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTl{LkG4JI5O	M1fWbnNCVkeHUh?=
CAL-85-1	NVHScJVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4L0UGlEPTB;OUKuOFghdk1?	NW\ufXNPW0GQR1XS
ES6	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDaTWM2OD17Mj64N{BvVQ>?	MXLTRW5ITVJ?
NCI-H650	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljNTWM2OD17ND6wPUBvVQ>?	NIfFPYpUSU6JRWK=
NCI-H446	M1nqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVG1Nm81UUN3ME25OU4yOiCwTR?=	M2P5Z3NCVkeHUh?=
EW-13	NUD4NFhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmT6TWM2OD17NT63OUBvVQ>?	M{K3U3NCVkeHUh?=
HSC-2	NWG0Ulc3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUW0emlpUUN3ME25OU45QSCwTR?=	Ml7WV2FPT0WU
U031	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIq0XnNKSzVyPUm2Mlc{KG6P	Mn\5V2FPT0WU
EW-11	NYXGbXBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;EfY1MUUN3ME25Ok45QCCwTR?=	NXXqcmV[W0GQR1XS
GAK	NG\BeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTncoV7UUN3ME25PE46OyCwTR?=	MYnTRW5ITVJ?
SK-OV-3	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLKTWM2OD1zMECuNFchdk1?	M1zrTHNCVkeHUh?=
OMC-1	NYi5[lJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1e5PGlEPTB;MUCwMlE5KG6P	MnHQV2FPT0WU
TK10	NXfCW5JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUf5SJZIUUN3ME2xNFAvOjFibl2=	MYrTRW5ITVJ?
EKVX	M4TQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTFyMD62JI5O	Mn\hV2FPT0WU
Detroit562	NYS4RY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFyMj6xO{BvVQ>?	MUnTRW5ITVJ?
SF268	NX;jU5R3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrzWGdTUUN3ME2xNFIvOzRibl2=	MmTOV2FPT0WU
SNU-387	M3\J[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDYTWM2OD1zMESuNVchdk1?	NVHR[W5IW0GQR1XS
MDA-MB-231	NXHjTJYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vUfGlEPTB;MUC1MlA3KG6P	M3OzPXNCVkeHUh?=
NCI-H1563	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17MTmlEPTB;MUC1MlE5KG6P	NY\LVIJoW0GQR1XS
D-502MG	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fyUmlEPTB;MUC1Mlchdk1?	MkmwV2FPT0WU
A2780	NITO[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\RfmlEPTB;MUC2MlQ4KG6P	NYP0VWFrW0GQR1XS
IA-LM	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLMTWM2OD1zMEeuOVEhdk1?	NHqwTZdUSU6JRWK=
D-392MG	M4Dv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2X3TWlEPTB;MUC3MlU1KG6P	NGLWe\|dUSU6JRWK=
MS-1	M3PKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTFTWM2OD1zMEeuO\|Ehdk1?	NFf0THlUSU6JRWK=
SW1990	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTETWM2OD1zMEiuOVQhdk1?	M1jMcnNCVkeHUh?=
HEL	M4G0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrvVYtDUUN3ME2xNFkvOjlibl2=	MYXTRW5ITVJ?
SW1573	MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;LN21OUUN3ME2xNFkvOzFibl2=	NEPFbFZUSU6JRWK=
SW1783	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTFzMD6yNkBvVQ>?	MmLsV2FPT0WU
COLO-680N	NWK4XGU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTFzMD63OkBvVQ>?	MkTaV2FPT0WU
NCI-N87	Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LzZWlEPTB;MUGxMlA1KG6P	NIPoR\|RUSU6JRWK=
SK-MEL-28	NHXlZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\ndnV5UUN3ME2xNVEvPTVibl2=	Mlj4V2FPT0WU
BT-20	NX\rO\|ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTFzMj6wNUBvVQ>?	NE\qdphUSU6JRWK=
NCI-H1648	NYLvdYNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXwPVlXUUN3ME2xNVMhdk1?	NYDJfnRYW0GQR1XS
no-11	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTFzMz6yPEBvVQ>?	Mm\IV2FPT0WU
MOLT-13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTSNJZXUUN3ME2xNVMvPDRibl2=	NVzrTXBsW0GQR1XS
NCI-H2170	M{Tu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1qxU2lEPTB;MUG0MlUyKG6P	MWfTRW5ITVJ?
HTC-C3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTybXZyUUN3ME2xNVYvQDVibl2=	Mmm0V2FPT0WU
LU-99A	NYPxcow3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFzNz6yNUBvVQ>?	NYTER4t7W0GQR1XS
HCC2998	NFriR\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml24TWM2OD1zMUeuPVIhdk1?	MnPMV2FPT0WU
NB13	M3z0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWX5UldWUUN3ME2xNVcvQTlibl2=	MWnTRW5ITVJ?
GT3TKB	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnjXTWM2OD1zMUiuNFghdk1?	Mk[wV2FPT0WU
BT-549	NG\NN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzC[pN2UUN3ME2xNVgvQTVibl2=	MmrvV2FPT0WU
NCI-H747	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlS0TWM2OD1zMUmuN\|Qhdk1?	MUXTRW5ITVJ?
EW-1	NG\PTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTF{MD6yJI5O	MVfTRW5ITVJ?
LB831-BLC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[3TWM2OD1zMkCuOlMhdk1?	M2HCfnNCVkeHUh?=
NMC-G1	NUHhNFVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXLRmtiUUN3ME2xNlEvOTFibl2=	NH3PNHpUSU6JRWK=
COLO-679	M4rnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTF{Mj6xOUBvVQ>?	NWHyfIZ1W0GQR1XS
HL-60	M{PYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3mcnlKSzVyPUGyN{4yKG6P	MUPTRW5ITVJ?
MKN7	NWDZcWI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTF{Mz64N{BvVQ>?	NHnQNFRUSU6JRWK=
RERF-LC-MS	NEP3dZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTF{ND6zNUBvVQ>?	M4jhZ3NCVkeHUh?=
DMS-114	M2fafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XtPGlEPTB;MUK1MlA6KG6P	NFvoXmpUSU6JRWK=
HuP-T4	MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HLdWlEPTB;MUK2Mlk4KG6P	Mn35V2FPT0WU
HCC2157	M3HLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfKSnNKSzVyPUGyO{42KG6P	M{PmWnNCVkeHUh?=
SKG-IIIa	MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTF{OD64JI5O	NGnn[3JUSU6JRWK=
HCT-116	NYfqZXZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DPN2lEPTB;MUOwMlY1KG6P	MW\TRW5ITVJ?
BB30-HNC	NEXTTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7mZ3Q{UUN3ME2xN\|AvPzhibl2=	MULTRW5ITVJ?
KYSE-270	NFu2XoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF\|MD64PEBvVQ>?	Mly2V2FPT0WU
MFM-223	Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTF\|MT61NUBvVQ>?	NW\GWG9MW0GQR1XS
NH-12	NHLO[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn[xTWM2OD1zM{KuPVkhdk1?	M4fGe3NCVkeHUh?=
U-118-MG	NGO4NHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjT[YRKSzVyPUGzN{43OiCwTR?=	MlXHV2FPT0WU
ESS-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jJfGlEPTB;MUO1MlE5KG6P	M4riO3NCVkeHUh?=
D-247MG	Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjnd4FqUUN3ME2xN\|UvOjFibl2=	NHPKcJZUSU6JRWK=
IGROV-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljqTWM2OD1zM{WuO\|Yhdk1?	MY\TRW5ITVJ?
C-33-A	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfGcW9KSzVyPUGzOU46PyCwTR?=	NGfBNYRUSU6JRWK=
NCI-H1693	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHaUYVKSzVyPUGzOk4yOiCwTR?=	M{GzZ3NCVkeHUh?=
MLMA	MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPKPIZKSzVyPUGzOk42QCCwTR?=	Mk\nV2FPT0WU
SK-N-AS	NFTvdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLjTWM2OD1zM{euNVchdk1?	M2jZeXNCVkeHUh?=
NCI-H1755	NEnCUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHO0fIdKSzVyPUGzPE45PSCwTR?=	NVXWUGJtW0GQR1XS
CHP-134	NUDUbm5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2foVWlEPTB;MUO5MlU2KG6P	MlTIV2FPT0WU
LS-513	MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPJXnNDUUN3ME2xOFAvQTFicF2=	Mk\RV2FPT0WU
TE-12	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\ZU5BXUUN3ME2xOFAvQTNibl2=	NXTDZZk2W0GQR1XS
KNS-42	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTHTWM2OD1zNESuN{BvVQ>?	M1P4U3NCVkeHUh?=
SJRH30	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTF2ND60OEBvVQ>?	NVSyT\|V2W0GQR1XS
NCI-H1092	NHrG[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnoV5pKSzVyPUG0OE42OiCwTR?=	M1;ydXNCVkeHUh?=
H-EMC-SS	NHLGcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfGTWM2OD1zNE[uPFEhdk1?	MVnTRW5ITVJ?
SK-MEL-3	NIHpXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHSzNYtKSzVyPUG0O{42PSCwTR?=	NYP4WmdVW0GQR1XS
SK-N-FI	M4ewSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoexTWM2OD1zNEeuOVkhdk1?	MlK1V2FPT0WU
NCI-H2126	NUnpfJlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTF2OD6xOUBvVQ>?	NIrNR29USU6JRWK=
NCI-H1299	Mn7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fsWWlEPTB;MUWwMlIzKG6P	NHzPR\|ZUSU6JRWK=
CFPAC-1	NHnFcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWW5eFUyUUN3ME2xOVAvPjZibl2=	NUW2cXRGW0GQR1XS
NCI-H661	MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\lTWM2OD1zNUGuNlYhdk1?	Mo\sV2FPT0WU
KYSE-70	MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;MTWM2OD1zNUGuO\|khdk1?	M3LwXHNCVkeHUh?=
SW900	NFHLdm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF3ND62OUBvVQ>?	NYXVd3R[W0GQR1XS
Ca-Ski	MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvsRWF4UUN3ME2xOVYvOzlibl2=	NFW4VldUSU6JRWK=
HPAF-II	NWC2[4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTF3Nj60O{BvVQ>?	MkjpV2FPT0WU
LB2518-MEL	NInpTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37VdmlEPTB;MUW3MlEhdk1?	MY\TRW5ITVJ?
LC-2-ad	MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;ieHpKSzVyPUG1PE43OiCwTR?=	M1i5PHNCVkeHUh?=
HCC1806	NWHFcnNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLFTWM2OD1zNkeuPFghdk1?	MVfTRW5ITVJ?
UACC-62	MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPuZWV7UUN3ME2xOlgvODlibl2=	NEPjVXRUSU6JRWK=
KM-H2	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfkSnNMUUN3ME2xO\|AvPThibl2=	M1j6PXNCVkeHUh?=
NCI-H2347	NYTjV5lPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLmN\|BkUUN3ME2xO\|IvPzJibl2=	M4rMNXNCVkeHUh?=
SCC-15	NWXBVmNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\vTWM2OD1zN{OuOlYhdk1?	MnLEV2FPT0WU
BB49-HNC	M1;NVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTF5Mz64NUBvVQ>?	M4flVnNCVkeHUh?=
GMS-10	NYHVSWtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTF5Mz65OEBvVQ>?	MU\TRW5ITVJ?
NCI-H2052	M4DpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIT1U3ZKSzVyPUG3OE46KG6P	MXfTRW5ITVJ?
SW626	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml32TWM2OD1zN{[uNFYhdk1?	MWHTRW5ITVJ?
MDA-MB-415	NWjlVopGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTF5Nj62NUBvVQ>?	MlH5V2FPT0WU
Saos-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDaVGJXUUN3ME2xO\|kvOzVibl2=	NXnqXYNXW0GQR1XS
DK-MG	NH7tSY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXH6b5A3UUN3ME2xPFAvOyCwTR?=	MVPTRW5ITVJ?
SNU-C2B	NGi2NVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1r3W2lEPTB;MUiwMlc{KG6P	M{\FUHNCVkeHUh?=
A427	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3QTWM2OD1zOEKuOVchdk1?	NIDPcmdUSU6JRWK=
KP-N-YS	NFqw[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrSO3NmUUN3ME2xPFUhdk1?	M3zBdnNCVkeHUh?=
J82	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHK4ZWlKSzVyPUG4OU4yQCCwTR?=	NXrQWYdwW0GQR1XS
LS-411N	NGfCeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{PlTWlEPTB;MUi3MlI5KG6P	MWXTRW5ITVJ?
HCC1937	NF73TodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLuSppkUUN3ME2xPFcvPDlibl2=	M3LOW3NCVkeHUh?=
OE33	NXjZcVR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTF6OD65O{BvVQ>?	MVLTRW5ITVJ?
NB7	NF7IPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfJUZpKSzVyPUG4PU45QSCwTR?=	M1SzXnNCVkeHUh?=
SW684	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPibndKSzVyPUG5Ok4yOyCwTR?=	M2HNbXNCVkeHUh?=
HT-144	M4LUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTF7Nj6xOUBvVQ>?	NHnkWGJUSU6JRWK=
SK-MEL-30	M4LtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvnTWM2OD1zOU[uNkBvVQ>?	M3;ZUnNCVkeHUh?=
DBTRG-05MG	NXPBVZRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTF7OD60O{BvVQ>?	MnXJV2FPT0WU
NCI-H1395	NULWfZJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIm5dYRKSzVyPUG5PE45PSCwTR?=	M{\RRXNCVkeHUh?=
NCI-H2122	M3fZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rDeWlEPTB;MkCwMlU6KG6P	M1HuOHNCVkeHUh?=
no-10	NF3zbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7UTWM2OD1{MEGuNFQhdk1?	MWPTRW5ITVJ?
SW48	M{HjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTJyMT6zNUBvVQ>?	M3zwUXNCVkeHUh?=
NCI-H1650	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTJyND6wNUBvVQ>?	MYTTRW5ITVJ?
MZ1-PC	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{KyVmlEPTB;MkC1MlU5KG6P	NHG2T3lUSU6JRWK=
U-266	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXDTWM2OD1{MEWuO\|khdk1?	MnfqV2FPT0WU
CAS-1	NXiwe5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnyzTWM2OD1{MEeuOFQhdk1?	NF;IOFlUSU6JRWK=
AU565	M4\obGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYj6cIpTUUN3ME2yNVIvQDJibl2=	M{mxTXNCVkeHUh?=
UACC-257	M4fFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfET\|RKSzVyPUKxN{46QSCwTR?=	NWHaWFZmW0GQR1XS
CAL-27	NGLRPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoT6TWM2OD1{MUeuNFUhdk1?	MXXTRW5ITVJ?
NCI-H23	NHq4SIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LWV2lEPTB;MkG5MlM{KG6P	NGfPfoRUSU6JRWK=
TE-6	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTJzOT62PEBvVQ>?	MYPTRW5ITVJ?
TGBC24TKB	NWnGTJdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvUTWM2OD1{MkKuNVchdk1?	M{PKfHNCVkeHUh?=
TE-1	M2[5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TDVWlEPTB;MkKyMlg5KG6P	M1jSRnNCVkeHUh?=
RCC10RGB	M2fqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnHeJBmUUN3ME2yNlQvOTlibl2=	MmW3V2FPT0WU
NCI-H596	NFTVO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTJ{OD6yNkBvVQ>?	NXnQV3VDW0GQR1XS
SW954	NWDSfHRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn[4TWM2OD1{M{OuPFMhdk1?	NVy1cHoxW0GQR1XS
NCI-H2087	NIjFbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHK4NZFKSzVyPUKzOE42OSCwTR?=	NVf3PFdCW0GQR1XS
SK-PN-DW	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTJ\|NT6xPUBvVQ>?	MVjTRW5ITVJ?
KM12	NHnWTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vZUmlEPTB;MkO1Mlchdk1?	NF2xPHNUSU6JRWK=
BT-474	NFP5cpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7ZTWM2OD1{M{WuO\|Mhdk1?	MXTTRW5ITVJ?
IST-MES1	NYX6NYQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mln6TWM2OD1{M{[uOVchdk1?	NG\lUZBUSU6JRWK=
HT-1197	M{fi[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf6PZVKSzVyPUKzPE4xQSCwTR?=	NFLXSIFUSU6JRWK=
CAL-54	NUSyS4ViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvYNIdKSzVyPUKzPE41QSCwTR?=	NV;JblRHW0GQR1XS
NB10	M3fkWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTyTWM2OD1{NECuNFYhdk1?	MVXTRW5ITVJ?
PANC-10-05	M{Pqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknvTWM2OD1{NEWuOVYhdk1?	M4izbXNCVkeHUh?=
NCI-H522	NUP3S\|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHudYdKSzVyPUK0PE4{OSCwTR?=	M2LETXNCVkeHUh?=
A388	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnFVopKSzVyPUK0PU45OiCwTR?=	MkXJV2FPT0WU
GOTO	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTJ3MD6yPUBvVQ>?	NUnIO5ZiW0GQR1XS
KLE	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zZZWlEPTB;MkWxMlg4KG6P	MojnV2FPT0WU
KYSE-520	MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fsU2lEPTB;MkWyMlg3KG6P	MVjTRW5ITVJ?
HCE-4	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLV[o8{UUN3ME2yOlIvPSCwTR?=	NX\xPHNQW0GQR1XS
KURAMOCHI	NX7UW\|g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJ4NT65JI5O	MYHTRW5ITVJ?
HCC38	NUmyWZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ4Nj60PEBvVQ>?	MX\TRW5ITVJ?
FADU	M{\ZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJ4Nj62N{BvVQ>?	Mo\hV2FPT0WU
CW-2	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPQN5ZYUUN3ME2yOlkvQTZibl2=	NVz1eIlYW0GQR1XS
L-428	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jwfWlEPTB;Mke1MlE2KG6P	M1rUUXNCVkeHUh?=
HCC1569	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTJ5NT64OEBvVQ>?	MYLTRW5ITVJ?
NCI-H810	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PMcWlEPTB;Mke4MlMyKG6P	M1j1cnNCVkeHUh?=
LB771-HNC	NHOxUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrPUXN1UUN3ME2yPFUvQDRibl2=	MVrTRW5ITVJ?
LCLC-103H	Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUmwU2NTUUN3ME2yPFUvQTlibl2=	M{W1RXNCVkeHUh?=
EFO-21	M{K3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTJ6Nz62PEBvVQ>?	NWPBVIx[W0GQR1XS
CAL-72	NEi4N\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTzO\|NKSzVyPUK5N{4yQSCwTR?=	NYHyRXh7W0GQR1XS
SCC-9	NHfFd5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTJ7Mz6yNkBvVQ>?	MlroV2FPT0WU
COLO-829	NYLNfHQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHufJluUUN3ME2yPVYvPSCwTR?=	MX;TRW5ITVJ?
U-87-MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTNyMD63N{BvVQ>?	NXjZT3NRW0GQR1XS
MZ7-mel	MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFL0TmVKSzVyPUOyN{44PiCwTR?=	NY[0VXR2W0GQR1XS
NCI-H1770	Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTZTWM2OD1\|Mk[uO\|Qhdk1?	NVnhUIM2W0GQR1XS
ChaGo-K-1	M2P6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTN{OD6xJI5O	NHHUPI5USU6JRWK=
SiHa	NH;pOGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTN{OT6yOEBvVQ>?	NYfhO446W0GQR1XS
NCI-SNU-5	NVOzS\|NkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLnZYV7UUN3ME2zN\|YvPzdibl2=	NE[0NWZUSU6JRWK=
DJM-1	M1q2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfyfWg1UUN3ME2zOFAvOzNibl2=	MmPqV2FPT0WU
OE19	MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvmTWM2OD1\|NECuOVMhdk1?	MoDOV2FPT0WU
NCI-H1651	NUHNenlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYS3XGVVUUN3ME2zOFQvOThibl2=	NFf5TpVUSU6JRWK=
COLO-792	NVfZUVZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XPNWlEPTB;M{W0MlQzKG6P	M4C3cHNCVkeHUh?=
ACHN	MlLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7WTWM2OD1\|NU[uO\|Ehdk1?	MXvTRW5ITVJ?
TH-3	M2LwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTN5OT65OUBvVQ>?	NE\BVI9USU6JRWK=
HT-1376	M4fYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\rcWlEPTB;M{i0Mlg5KG6P	MmX3V2FPT0WU
RH-18	NEnLTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nPcmlEPTB;M{m0Mlc1KG6P	NXzOfIJJW0GQR1XS
NB6	NX\mO\|JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvnU3lKSzVyPUO5Ok43PiCwTR?=	MYTTRW5ITVJ?
COLO-320-HSR	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzOe5I4UUN3ME20NFMvOzdibl2=	M1XMdHNCVkeHUh?=
UACC-893	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXqxdIxkUUN3ME20NFYvPDdibl2=	M3TjdnNCVkeHUh?=
DSH1	NHzZ[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTRyNj65NUBvVQ>?	NEf1S\|RUSU6JRWK=
TE-10	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYD1O2o5UUN3ME20NFcvODFibl2=	NH;XVoVUSU6JRWK=
HCC70	NXHBeoxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTRyOT6yNUBvVQ>?	MmLCV2FPT0WU
TGBC11TKB	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDWTWM2OD12MUCuN\|Mhdk1?	MWTTRW5ITVJ?
NCI-H727	NFzIb41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mle2TWM2OD12MUKuNVEhdk1?	MkfjV2FPT0WU
ALL-PO	M3v3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnUenVPUUN3ME20NVUvPjlibl2=	NGSxOYZUSU6JRWK=
ABC-1	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofzTWM2OD12MkCuOFUhdk1?	MnnjV2FPT0WU
NCI-H69	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXOzUpNHUUN3ME20NlYvPzZibl2=	M3;OOXNCVkeHUh?=
GP5d	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTYeHBKSzVyPUSzOE41OSCwTR?=	M{j0PHNCVkeHUh?=
UMC-11	M{HyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYn3bVRFUUN3ME20OVgvOzZibl2=	NFm0XnZUSU6JRWK=
RMG-I	M3PaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjBWoNKSzVyPUS2O{42PiCwTR?=	M4KxNXNCVkeHUh?=
YAPC	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHLXRWdKSzVyPUS5NE43KG6P	M4LFcHNCVkeHUh?=
LS-1034	MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y3VWlEPTB;NEmxMlA3KG6P	M4TYTHNCVkeHUh?=
RCM-1	NGHCTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\2SIpKSzVyPUS5Ok43QCCwTR?=	NWnQU3pxW0GQR1XS
HCC1954	NGjHc3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\uZ2dKSzVyPUWxNk42KG6P	Mlz3V2FPT0WU
SK-MEL-24	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TWemlEPTB;NUG2MlUyKG6P	M4nIcXNCVkeHUh?=
NB12	NWLuSmN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTV{OD60NkBvVQ>?	MkXzV2FPT0WU
SW756	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTV3ND65OkBvVQ>?	M2H3R3NCVkeHUh?=
HCC1187	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\GTXBYUUN3ME21O\|UvQDNibl2=	MVPTRW5ITVJ?
NCI-H2342	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13sUGlEPTB;NUmwMlM6KG6P	MlTIV2FPT0WU
NCI-H2291	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTV7OD6zNUBvVQ>?	MXfTRW5ITVJ?
OVCAR-3	Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXxNZVKSzVyPUW5PE46PiCwTR?=	M4Hnc3NCVkeHUh?=
MHH-NB-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm[1TWM2OD14MkmuNFEhdk1?	MVnTRW5ITVJ?
SAS	NUD0UVRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnPTWM2OD14NUKuOlchdk1?	M4rzbXNCVkeHUh?=
COLO-824	NUPTT29oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4nkfWlEPTB;Nki5MlM4KG6P	NVHZ[Yh7W0GQR1XS
HCC1395	NXjEeWN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\kTGRSUUN3ME22PVgvPSCwTR?=	MnXxV2FPT0WU
COLO-668	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnx[GxKSzVyPUewOk4yKG6P	Ml65V2FPT0WU
NCI-H226	NGPTfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmWxTWM2OD15MEeuPEBvVQ>?	NG\DXG1USU6JRWK=
NB17	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm[wTWM2OD15MkGuO\|Uhdk1?	MlPmV2FPT0WU
SW1463	MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnSZ\|BKSzVyPUezPU4yQSCwTR?=	MmLHV2FPT0WU
TGW	NFXuUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD5TWM2OD15NkCuNVUhdk1?	MV\TRW5ITVJ?
NCI-H526	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTh{Mz61N{BvVQ>?	NXr6V206W0GQR1XS
COR-L88	M1XQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zvb2lEPTB;OES4MlEzKG6P	NUGySHlzW0GQR1XS
NCI-H441	M{TnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnyxTWM2OD16OUWuNlIhdk1?	MnjOV2FPT0WU
NCI-H630	M2nkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV30dodvUUN3ME25NVIvQTZibl2=	MlPuV2FPT0WU
Mo-T	NHzQXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUO1fld7UUN3ME25OFcvQDhibl2=	MWDTRW5ITVJ?
JAR	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGi0fYtKSzVyPUm1Ok4zPCCwTR?=	NGDMeolUSU6JRWK=
NCI-H1838	NFHadY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TLWmlEPTB;MT6wNlM5QCEQvF2=	M3vBS3NCVkeHUh?=
DoTc2-4510	M2njeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TkR2lEPTB;MT6wO\|M4PiEQvF2=	MYLTRW5ITVJ?
MKN28	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTFwMEmwNlQh\|ryP	NHPSUYpUSU6JRWK=
HuP-T3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mme5TWM2OD1zLkGxPVA2KM7:TR?=	Mlu4V2FPT0WU
TE-9	NV;v[FdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\WUIFPUUN3ME2xMlEzQTd\|IN88US=>	M1fwXHNCVkeHUh?=
NY	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljBTWM2OD1zLkG2O\|kzKM7:TR?=	NFrnWXRUSU6JRWK=
HT55	NHfMcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF60ZmZKSzVyPUGuN\|E{PDRizszN	NX;jfoR1W0GQR1XS
SW837	M2jaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzOPXp3UUN3ME2xMlMzQTd6IN88US=>	MYfTRW5ITVJ?
NCI-H2029	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzGNm9FUUN3ME2xMlQyPzlzIN88US=>	NYrKXmFPW0GQR1XS
IST-SL1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzNTWM2OD1zLkS0NlQh\|ryP	NH7DWm1USU6JRWK=
COLO-741	NX\tUFdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\TbFRLUUN3ME2xMlQ6PzdzIN88US=>	M3PpRnNCVkeHUh?=
LU-65	NGjqWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\GXGdFUUN3ME2xMlYzOjR7IN88US=>	MX\TRW5ITVJ?
NCI-H1304	NYjwUYNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7rPI9nUUN3ME2xMlY2PDl6IN88US=>	M3\0THNCVkeHUh?=
KARPAS-299	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEn1V49KSzVyPUGuO\|k1PzlizszN	NFPIfZlUSU6JRWK=
NCI-H358	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrMbXpKSzVyPUGuPVU2ODNizszN	NEmxbmhUSU6JRWK=
OAW-28	NFrnRo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljBTWM2OD1{LkC2PVE6KM7:TR?=	NYDOS4VFW0GQR1XS
C8166	NWnUOm8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{ThS2lEPTB;Mj62N\|M6OiEQvF2=	NHTrbmFUSU6JRWK=
COLO-678	M2flNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\je4FmUUN3ME2yMlg{PzZ6IN88US=>	MYfTRW5ITVJ?
SK-N-DZ	NITHenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTJwOE[zPFEh\|ryP	MoPYV2FPT0WU
NCI-H82	NVPDeFBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n1VGlEPTB;Mj65NFM3QSEQvF2=	M3TLTHNCVkeHUh?=
JVM-2	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnyTpFwUUN3ME2zMlA{OTh6IN88US=>	NUjKN3RGW0GQR1XS
SW1116	M1;aPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvGTWM2OD1\|LkC1OFEyKM7:TR?=	MYHTRW5ITVJ?
MDA-MB-453	NFLFe\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPFTWM2OD1\|LkGwOFM6KM7:TR?=	MXzTRW5ITVJ?
Calu-6	NVLHe3JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vpOGlEPTB;Mz6xPVk4KM7:TR?=	MWfTRW5ITVJ?
SHP-77	M2XW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LyZmlEPTB;Mz61Nlgh\|ryP	M2L2XXNCVkeHUh?=
Capan-2	NU\TTGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH63NnVKSzVyPUSuN\|I2QDFizszN	M2n5dXNCVkeHUh?=
SW948	M2TKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTRwN{S3O\|kh\|ryP	NFjTR3JUSU6JRWK=
HDLM-2	NFfFfW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofOTWM2OD13LkC3O\|I2KM7:TR?=	M4DwdXNCVkeHUh?=
LAN-6	NX3FVpE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLDOppEUUN3ME22MlIyPDl3IN88US=>	MnXOV2FPT0WU
LU-135	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjpUmdlUUN3ME22MlQ{ODd5IN88US=>	MX3TRW5ITVJ?
T84	NEfX[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHxXGlKSzVyPU[uPVg3PCEQvF2=	M1rNbnNCVkeHUh?=
CAPAN-1	NEPKR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTdwNkKyN\|Mh\|ryP	M{fxSXNCVkeHUh?=
SW1417	MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XGcmlEPTB;Nz65NVc{OSEQvF2=	MXfTRW5ITVJ?
BALL-1	M3nUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHniRWJKSzVyPUiuOVA1ODlizszN	M1zNcnNCVkeHUh?=
HT-29	NXj6XJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDnZ3BKSzVyPUmuNFc2QTlizszN	NGO2[IdUSU6JRWK=
C3A	NILoZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDKTWM2OD17Lki4N\|k1KM7:TR?=	MnHKV2FPT0WU
NCI-H1993	NYrpcmVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DSW2lEPTB;MUCuOVA5OSEQvF2=	NWnaNGZkW0GQR1XS
SK-MEL-1	M3j0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLjUG9KSzVyPUGxMlYzQDlizszN	M{\hVnNCVkeHUh?=
DU-145	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXSZZJoUUN3ME2xOE42ODV{IN88US=>	MmDUV2FPT0WU
KP-N-YN	NF\1[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\ieGlEPTB;MUSuOVExOyEQvF2=	MlmzV2FPT0WU
CCRF-CEM	Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3yzV2lEPTB;MUSuO\|gxQSEQvF2=	NYj4UJB5W0GQR1XS
ZR-75-30	NU\OT5dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;Dd3dZUUN3ME2xOk4{OzB\|IN88US=>	MXvTRW5ITVJ?
A673	NGj5eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3ju[GlEPTB;MkCuOVUxPyEQvF2=	MmrkV2FPT0WU
K-562	MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HYbmlEPTB;MkiuOFE5OyEQvF2=	MmfDV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1; PubMed: 26336820 Oncotarget Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF. p-ErbB2(Y1248); PubMed: 24675532 Cell Res Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm. LC3; PubMed: 23603977 Acta Pharmacol Sin (A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).	26336820 24675532 23603977
Growth inhibition assay	Cell viability (P3, U87); PubMed: 27542970 BMC Cancer IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. Cell viability (breast cancer cells); PubMed: 28060760 Oncotarget Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. Cell viability (K562, KBM7R); PubMed: 28435223 Drug Des Devel Ther (A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.	27542970 28060760 28435223
ELISA	VEGF; PubMed: 19671762 Mol Cancer Ther NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.	19671762

In vivo

BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro Protein Kinase, PI3K, and mTOR Assays: PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH₂-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research: ^[2]	- Collapse Cell lines: HCT116, DLD-1 and SW480 cells Concentrations: 0-1 μM Incubation Time: 48 hours Method: The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 10³ cells/well, DLD-1: 5.5 × 10³ cells/well, SW480: 4.5 × 10³ cells/well, DLD-1 PIK3CA mutant: 7 × 10³ cells/well, and DLD-1 PIK3CA wild-type: 9 × 10³ cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female Harlan athymic nude mice Dosages: 45 mg/kg Administration: p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMF	18 mg/mL warmed (38.33 mM)
	DMSO	0.01 mg/mL (0.02 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): NMP+PEG300 (10+90, v+v) For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dactolisib (BEZ235) SDF

Molecular Weight	469.55
Formula	C₃₀H₂₃N₅O
CAS No.	915019-65-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-BEZ235
Smiles	CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01856101	Terminated	Drug: BEZ235	Carcinoma Transitional Cell	Cliniques universitaires Saint-Luc- Université Catholique de Louvain\|Novartis	February 2013	Phase 2
NCT01717898	Terminated	Drug: BEZ235\|Drug: Prednisone\|Drug: Abiraterone acetate	Castrate-resistant Prostate Cancer	Charles Ryan\|Novartis Pharmaceuticals\|University of California San Francisco	January 31 2013	Phase 1\|Phase 2
NCT01756118	Unknown status	Drug: BEZ235	Acute Lymphoblastic Leukemia\|Leukemia Myelocytic Acute\|Chronic Myelogenous Leukemia With Crisis of Blast Cells	Johann Wolfgang Goethe University Hospital	June 2012	Phase 1
NCT01290406	Withdrawn	Drug: BEZ235	Endometrial Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2
NCT01288092	Withdrawn	Drug: BEZ235	Metastatic Breast Cancer	Novartis Pharmaceuticals\|Novartis	March 2012	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
With difficulties in dissolving BEZ235, How can I improve its solubility?
Answer:
For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Selective PI3K Inhibitors

CAL-101 (Idelalisib, GS-1101) : p110δ-selective, IC50=2.5 nM.
Selective PI3K Inhibitors

TGX-221 : p110β-specific, IC50=5 nM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.
Wortmannin

Wortmannin (KY 12420) is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.
Buparlisib (BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.
Pictilisib (GDC-0941)

Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Dactolisib (BEZ235)